HERON THERAPEUTICS, INC. /DE/ 8-K

What Happened

• On April 3, 2026 Heron Therapeutics (HRTX) amended CEO Craig Collard’s employment agreement and entered into amended and restated management retention agreements with Executive VP/CFO Ira Duarte, EVPP/Chief Development Officer William Forbes, and COO Mark Hensley. The amendments revise termination payments, equity‑award treatment on termination or a change in control (CIC), bonus mechanics, and update governing law and restrictive covenants to North Carolina.
• Key changes for Collard: if terminated without Cause or he resigns for Good Reason outside the CIC Termination Window he receives a lump sum equal to 100% of annual base salary plus 100% of the greater of target bonus or three‑year average bonus, acceleration of equity vesting equal to 12 months of continued service, and up to 18 months of company‑paid COBRA. If termination occurs during the CIC Termination Window, payments increase to 200% of salary and 200% of bonus (or average), full acceleration of outstanding equity, and up to 24 months COBRA. Performance awards granted after the amendment use a “Performance‑Based Vesting Criteria” (treated at the greater of actual performance to date or target).
• Key changes for Duarte, Forbes and Hensley: for an Involuntary Termination outside the CIC window each executive gets 12 months of base salary plus 100% of the greater of target or average bonus, 12 months’ pro‑rata acceleration of service‑based equity (with a special immediate vesting rule for certain Hensley options), and up to 12 months COBRA. If the Involuntary Termination occurs during the CIC Termination Window, each exec receives 24 months of salary, 200% of bonus, full acceleration of equity, and up to 24 months COBRA. All three agreements add enhanced confidentiality, invention assignment, and 24‑month non‑compete/non‑solicit covenants and set North Carolina as governing law.

Key Details

• Effective date: April 3, 2026.
• CEO Collard severance: 100% salary + 100% bonus (outside CIC window); 200% salary + 200% bonus (during CIC window).
• Execs Duarte, Forbes, Hensley severance: 12 months salary + 100% bonus (outside CIC); 24 months salary + 200% bonus (during CIC).
• Equity treatment: 12‑month vesting acceleration outside CIC (full acceleration during CIC); performance awards post‑amendment use the greater of achieved performance to date or target for vesting. COBRA continuation up to 12–24 months depending on role and circumstance.

Why It Matters

• These changes increase executive severance and strengthen equity acceleration protections, especially in connection with a change in control, which could affect post‑transaction compensation costs and dilution timing for shareholders.
• Investors should note the longer non‑compete/safety covenants and the North Carolina governing law change, which may affect executive departure negotiations and enforcement.
• No financial results were reported in this filing; the item is focused on personnel contract terms that could influence future cash severance and equity outcomes.